Patton Fund Management Inc. Makes New Investment in Insulet Corporation $PODD

Key Points

• Patton Fund Management Inc. acquired 844 shares of Insulet Corporation (NASDAQ:PODD), valued at approximately $265,000, during the 2nd quarter.
• Insulet reported $1.17 EPS for the recent quarter, beating estimates and showing a 32.9% increase in revenue year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for Insulet, with an average price target of $343.06.

Patton Fund Management Inc. acquired a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 844 shares of the medical instruments supplier's stock, valued at approximately $265,000.

Several other institutional investors also recently bought and sold shares of the company. Mackenzie Financial Corp increased its holdings in shares of Insulet by 7.0% in the 4th quarter. Mackenzie Financial Corp now owns 7,561 shares of the medical instruments supplier's stock valued at $1,974,000 after acquiring an additional 493 shares during the period. Siemens Fonds Invest GmbH acquired a new stake in Insulet during the 4th quarter worth about $201,000. Wealth Enhancement Advisory Services LLC lifted its position in Insulet by 16.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 2,658 shares of the medical instruments supplier's stock worth $694,000 after acquiring an additional 384 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in Insulet by 23.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after acquiring an additional 59 shares during the period. Finally, AdvisorNet Financial Inc lifted its position in Insulet by 17.6% during the 1st quarter. AdvisorNet Financial Inc now owns 750 shares of the medical instruments supplier's stock worth $197,000 after acquiring an additional 112 shares during the period.

Insider Activity

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Price Performance

Shares of Insulet stock opened at $318.00 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a twelve month low of $225.37 and a twelve month high of $353.50. The business has a 50-day moving average price of $319.01 and a 200 day moving average price of $296.97. The firm has a market cap of $22.38 billion, a PE ratio of 96.66, a P/E/G ratio of 2.64 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the previous year, the business earned $0.55 EPS. Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Canaccord Genuity Group lifted their price target on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Truist Financial assumed coverage on Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Piper Sandler lifted their price target on Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 16th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $343.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.